Pharmacopeia

Canonical comparison

Master Compare

Compare candidate-facing canonical Pharmacopeia fields side by side. Isolated AI-draft proposals are never included.

3selected

Field	TICAGRELOR Haematology · Haematology · Level 2	ABCIXIMAB Haematology · Haematology · Level 3	TIROFIBAN Haematology · Haematology · Level 3
Mechanism of action	Allosteric, reversible antagonist at P2Y12-R (an ADP receptor), preventing activation of glycoprotein IIb/IIIa→ prevents platelet crosslinking	Similar mechanism as tirofiban but monoclonal antibody	Antagonises the GpIIb/IIIa receptor, preventing the binding of fibrinogen and platelet crosslinking and aggregation.
Absorption	BA=40%	—	—
Metabolism	Metabolized by CYP3A4	Platelet function typically returns to normal 24-48 hours after infusion ceases	Limited metabolism in humans.
Excretion	—	Platelet function typically returns to normal 24-48 hours after infusion ceases	Excreted in urine and faeces, mostly unchanged
Half-life	—	—	HL 1.9-2.2 hrs
Adverse Effects Toxicity	—	Haemorrhage, thrombocytopenia, human antichimeric antibody development, allergic reaction	Haemorrhage Difficulty reversing agent Dose adjustment in renal impairment
Class Group	Antiplatelet	Antiplatelet	Antiplatelet
Introduction	ADP Receptor Antagonist - Thienopyridine	GP IIb/IIIA Inhibitor	GP IIb/IIIA Inhibitor
Legacy Cicm Level	Level 3	Level 3	Level 3
Main Action	Platelet inhibition	Platelet inhibition	Platelet inhibition